Fox Run Management L.L.C. Makes New Investment in Tarsus Pharmaceuticals, Inc. $TARS

Fox Run Management L.L.C. purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 8,437 shares of the company’s stock, valued at approximately $501,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 5.5% in the third quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after buying an additional 136,582 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $14,264,000. TFG Asset Management GP Ltd grew its holdings in shares of Tarsus Pharmaceuticals by 40.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock worth $10,128,000 after acquiring an additional 71,530 shares during the period. TimesSquare Capital Management LLC purchased a new position in Tarsus Pharmaceuticals in the 3rd quarter valued at approximately $15,898,000. Finally, Jump Financial LLC raised its holdings in Tarsus Pharmaceuticals by 385.9% during the second quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock worth $9,606,000 after purchasing an additional 188,317 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ TARS opened at $75.52 on Friday. The firm has a market cap of $3.21 billion, a P/E ratio of -46.62 and a beta of 0.57. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.25 and a current ratio of 3.85. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25. The firm’s 50 day moving average price is $72.00 and its 200 day moving average price is $68.73.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. As a group, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on TARS shares. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $87.00.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider directly owned 38,958 shares in the company, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer directly owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 8.97% of the company’s stock.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.